• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

COVID-19 mRNA-1273 vaccine safe and immunogenic in phase 1 trial

byDarve RobinsonandDeepti Shroff Karhade
July 31, 2020
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The mRNA-1273 SARS-CoV-2 (COVID-19) vaccine was shown to be safe and immunogenic amongst the 45 COVID-19 negative participants in this phase 1 clinical trial, when compared to serum convalescent plasma

2. Only patients in the highest 2 dosage groups experienced a severe febrile episode after the 2nd dose was administered.

Evidence Rating Level: 2 (Good)

Study Rundown: The mRNA-1273 SARS-CoV-2 (COVID-19) vaccine, which encodes a stabilized perfusion spike trimer (S-2P), was designed and tested in a phase 1 clinical trial 66 days after the release of the COVID-19 genomic sequence.  It was designed and manufactured by Moderna and was administered as a 0.5ml injection into the deltoid muscle across two administrations (day 1 and 29).  A total of 45 participants received at least one of the two injections with all participants able to attend scheduled clinical follow up.  Amongst phase 1 participants, the 2-dose administered vaccine was completed without serious toxicity. A majority of the known reactogenicity occurred after the second dose was administered in 250-microgram group (with most reporting a post injection fever).  The mRNA-1273 vaccine was immunogenic and caused binding antibody IgG to rapidly increase such that all were seroconverted by day 15. All participants developed a binding antibody response to both full-length S-2P and receptor-binding domains. This response was similar to the effects seen in convalescent serum gathered from patient’s previously infected with COVID-19.

Click to read the study in NEJM 

Relevant Reading: Draft landscape of COVID-19 candidate vaccines—World Health Organization  

RELATED REPORTS

Worsening kidney function observed following SARS-CoV-2 infection in children

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

In-Depth [prospective cohort]: This phase 1, dose-escalation, open-label clinical trial research study aimed to assess the safety, reactogenicity and immunogenicity of the mRNA-1273 COVID-19 vaccine. Patients were between 18 and 55 and received 2 injections 28 days apart at 25 micrograms, 100 micrograms or 250 micrograms dosage.  The candidate vaccine encoded the S-2P antigen which consist of the glycoprotein of the COVID-19 with a transmembrane anchor and intact cleavage sites at S1-S2.  Dosage days were day 1 and 28 with follow up occurring 7- and 14-days post injection and days 57, 119, 209, and 394.  Binding antibody responses were assessed via ELISA, PsVNA, and PRNT assays on specimens collected from all participants on days 1, 15, 29, 36, 43, 57.  Reactogenicity was assessed by exploring via an intracellular cytokine-staining assay. Study findings noted that 5 members of the 25 microgram group, 10 in the 100 microgram group and 8 in the 250 microgram group had systemic adverse effects that were mild or moderate after the first administration and after the 2nd administration, 7/14 for the 25 microgram group and all of the 100 microgram and 250 microgram group reports systemic adverse effects.  Binding antibodies increased rapidly after the first administration of each vaccine and after the 2nd administration all participants had detected PsVNA response in serum samples. The 25 microgram and 100 microgram dose group elicited CD4 T-cell response that led towards expression of Th1 cytokines.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CoronavirusmRNA vaccinemRNA-1273 vaccineSARS-CoV-2
Previous Post

Prior tonsillectomy associated with increased risk of developing esophageal adenocarcinoma #TA

Next Post

#VisualAbstract: Effect of continuous glucose monitoring on glycemic control in young adults with type 1 diabetes

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Worsening kidney function observed following SARS-CoV-2 infection in children

May 23, 2025
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Hematology

Increased blood–urea–nitrogen-to-albumin ratio associated with increased mortality in coronavirus disease

February 10, 2025
Compliance-linked incentives increase infant immunizations rates in rural India
Chronic Disease

Safety of simultaneous vs sequential mRNA COVID-19 and inactivated influenza vaccines

November 17, 2024
#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19
StudyGraphics

#VisualAbstract: Oral Nirmatrelvir-Ritonavir Postexposure Prophylaxis Does Not Reduce the Risk of Developing Symptomatic Covid-19

August 12, 2024
Next Post
#VisualAbstract: Effect of continuous glucose monitoring on glycemic control in young adults with type 1 diabetes

#VisualAbstract: Effect of continuous glucose monitoring on glycemic control in young adults with type 1 diabetes

#VisualAbstract: Effect of continuous glucose monitoring on glycemic control in young adults with type 1 diabetes

#VisualAbstract: Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa

#VisualAbstract: A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19 did not show any benefit

#VisualAbstract: A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19 did not show any benefit

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.